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Abstract
Heart failure (HF) is an emerging epidemic associate 
with significant morbidity, mortality, and health care 
expenditure. Although there were major advances 
in pharmacologic and device based therapies for 
the management of HF, mortality of this condition 
remains high. Accurate monitoring of HF patients for 
exacerbations is very important to reduce recurrent 
hospitalizations and its associated complications. 
With the failure of clinical signs, tele-monitoring, and 
laboratory bio-markers to function as early markers of 
HF exacerbations, more sophisticated techniques were 
sought to accurately predict the circulatory status in 
HF patients in order to execute timely pharmacological 
intervention to reduce frequent hospitalizations. 
CardioMEMSTM (St. Jude Medical, Inc., Saint Paul, 
Minnesota) is an implantable, wireless pulmonary arterial 
pressure (PAP) monitoring system which transmits the 
patient’s continuous PAPs to the treating health care 
provider in the ambulatory setting. PAP-guided medical 
therapy modification has been shown to significantly 
reduce HF-related hospitalization and overall mortality. In 
advanced stages of HF, wireless access to hemodynamic 
information correlated with earlier left ventricular assist 
device implantation and shorter time to heart trans-
plantation.
Key words: CardioMEMS; Heart failure; Remote heart 
failure monitoring; Pulmonary arterial pressure moni-
toring; Left ventricular assist device
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Traditional heart failure monitoring methods 
have failed to accurately and timely identify worsening 
heart failure. Remote pulmonary artery pressure 
monitoring via  CardioMEMSTM heart failure system 
identified heart failure exacerbations earlier and more 
accurately than clinical signs, and timely medical 
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interventions resulted in reduced hospitalizations and 
mortality. Remote pulmonary artery pressure monitoring 
appears to have positive clinical implications in patients 
with mechanical circulatory support.
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INTRODUCTION
Heart failure (HF) is a chronic debilitating condition 
which impairs the ability of the heart to effectively pump 
the blood to the body to meet its metabolic require­
ments. HF is an emerging epidemic with an estimated 
prevalence of 5.8 million in the United States, and 
over 23 million worldwide[1]. Within the United States, 
the incidence of HF exceeds 650000 each year with 
an estimated annual financial burden of around 30.7 
billion dollars[2,3]. Although there were major advances 
in pharmacologic and device based therapies for the 
management of HF which improved the overall survival 
over time, mortality of this condition remains high. The 
estimated survival after the diagnosis of HF is 50% at 5 
years and 10% at 10 years[1]. Hospitalization for acute 
decompensated HF serves as a poor prognostic indicator 
with an approximate 30% and 50% readmission rates 
at 1­mo and 6­mo, respectively[1,3]. With improved 
survival of patients after acute myocardial infarction, a 
growing elderly population, and frequent hospitalizations 
in the HF population owing to acute exacerbations, HF 
continuous to be one of the leading causes of morbidity, 
mortality, and health care expenditures in the United 
States and worldwide.
Around 150000­250000 Americans suffer from 
advanced stage HF[4]. Although cardiac transplantation 
is the gold standard treatment in such patients, 
limited organ availability restricts the number of heart 
transplants to around 2500 per year (https://www.unos.
org/data/transplant­trends/#transplants_by_organ). 
More than 4000 patients are currently on the waiting 
list for a cardiac transplant (www.unos.org/data/
transplant­trends/#waitlists_by_organ), a number 
which is expected to increase significantly because of 
the increasing number of patients living with advanced 
HF and an increasing elderly population. Left ventricle 
assist device (LVAD) has emerged as a life­saving 
option for these patients as either bridge to transplant, 
bridge to decision, bridge to recovery or as destination 
therapy. Around 15000 HF patients across the world 
are currently supported with LVADs[5]. LVAD serves as 
destination therapy in more than 45% of the patients 
living with the device[5].
PREVIOUSLY TESTED METHODS FOR 
MONITORING HF PATIENTS
Identification of physical manifestations such as weight 
gain, extremity edema, fatigue, shortness of breath, 
orthopnea, paroxysmal nocturnal dyspnea, jugular 
venous distention, third heart sounds, and rales, etc. 
have poor to moderate sensitivities and are often late 
manifestations of worsening HF, thereby, relying on 
these markers have limited impact on reducing HF 
hospitalizations[6]. Also, such efforts largely employ 
patient self­management strategies, including diuretic 
dose adjustments based on clinical worsening, and are 
unsuccessful in patients with poor self­care skills and 
compliance[6]. Two large trials which investigated the 
benefits of tele­monitoring in HF population failed to 
show any significant decrease in the all-cause mortality 
and HF hospitalizations in the tele­monitored group[6]. A 
smart­phone based electrocardiographic monitoring of 
HF has been recently proposed, but there is not much 
data exploring this idea[7].
Lainchbury et al[8] compared N­terminal pro­B­
type natriuretic (NT­proBNP) guided titration of medical 
therapy in HF patients with intensive clinical manage­
ment and with usual care in a randomized sample of 564 
patients. There was a reduction in the 3­year mortality 
in the NT­proBNP­guided group compared to the 
clinically­guided group (30.9%; P = 0.048) and to those 
with usual care (31.3%; P = 0.021). These benefits 
were selectively seen in patients ≤ 75 years of age. 
However, there was no statistically significant difference 
in the overall hospitalizations for HF and the secondary 
outcomes among all the groups[8]. Another study 
monitored plasma B­type natriuretic peptide (BNP) levels 
in up to 558 chronic stable HF patients in an ambulatory 
setting to predict imminent decompensation[9]. The 
study showed that both symptomatic and asymptomatic 
HF patients had a wide range of plasma BNP levels. 
Interestingly, 21% of symptomatic decompensated HF 
patients had BNP levels below the diagnostic threshold 
of < 100 pg/mL[9].
REMOTE HEMODYNAMIC MONITORING 
IN HF PATIENTS
With the failure of reliable clinical symptoms/signs, tele­
monitoring, and laboratory bio­markers to help reduce 
the hospitalizations, and health care expenditure in the 
HF population, more sophisticated techniques were 
sought to accurately predict the circulatory status in 
HF patients in order to execute timely pharmacological 
intervention to prevent the primary onus of this disease, 
i.e., hospitalizations. Echocardiography is being used as 
a monitoring system in the hospitalized and ambulatory 
population, but it is associated with significant costs, 
less accuracy, and observer variability. Traditionally, 
in hospitalized HF patients, right heart catheterization 
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(RHC) provides invaluable information regarding the 
volume status and filling pressures which can form the 
basis of successful medical management. However, RHC 
is not routinely recommended to aid in the management 
of hospitalized decompensated HF patients owing to 
its invasive nature and associated risks. We had no 
such accurate monitoring systems in the ambulatory 
setting until scientific advances led to the development 
of implantable hemodynamic monitors (IHMs) which 
provided hemodynamic information comparable to the 
information obtained from a RHC[10]. The idea of IHM 
based monitoring and necessary interventions in HF 
patients was innovative and exiting. 
Earlier trials of implantable hemodynamic monitoring 
in HF patients did not show significant clinical benefit 
or were unable to adequately assess clinical efficacy. 
The COMPASS­HF (Chronicle Offers Management to 
Patients with Advanced Signs and Symptoms of Heart 
Failure) trial using Chronicle (Medtronic Inc., Minneapolis, 
Minnesota) to estimate right ventricular pressures 
and guide medical therapy, did not show a significant 
reduction in HF­related events when compared to the 
control group[11]. The Reducing Decompensation Events 
Utilizing Intracardiac Pressures in Patients With Chronic 
Heart Failure (REDUCEhf ) study employed a device 
combining IHM and implantable cardioverter-defibrillator 
technology to measure right ventricular pressures and 
guide medical therapy[12]. The REDUCEhf study was 
unable to test clinical efficacy end points adequately and 
findings from this study did not show a difference in the 
rate of HF­equivalents when medical therapy was guided 
based on the information obtained from the IHM[12]. 
The Hemodynamically Guided Home Self­Therapy 
in Severe Heart Failure Patients (HOMEOSTASIS) trial 
is a small study of 40 patients in which the benefit of 
physician­directed patient self­management of left atrial 
pressures as measured with the implantable HeartPOD 
(St. Jude Medical Inc, Minneapolis, Minnesota) was inves­
tigated[13]. Left atrial pressure guided medical therapy 
was associated with an improved event­free survival 
(death or hospitalization for acute decompensated 
HF), reduced mean daily left atrial pressures, improved 
New York Heart Association (NYHA) functional class, 
improved left ventricular ejection fraction, increased 
doses of neuro­hormonal antagonists, and reduced 
diuretic doses[13]. Encouraging results from this smaller 
study formed the basis of the larger and currently 
ongoing LAPTOP­HF trial which will investigate the role of 
implantable left atrial pressure monitoring in conjunction 
with a new HF treatment paradigm across the spectrum 
of HF patients[14].
CARDIOMEMSTM AND REMOTE 
PULMONARY ARTERIAL PRESSURE 
MONITORING
CardioMEMSTM (St. Jude Medical, Inc., Saint Paul, 
Minnesota) is a wireless pulmonary arterial (PA) 
23 January 26, 2017|Volume 9|Issue 1|WJC|www.wjgnet.com
pressure monitoring system. It measures PA pressures 
from a battery free capacitive electromechanical 
sensor which is permanently implanted with a delivery 
system in the distal pulmonary artery with a RHC via 
transvenous access. An electronic system transmits the 
generated data to a secure network where it is readily 
available for interpretation by the treating clinician. 
Verdejo et al[15] showed that wireless PA pressure moni­
toring using the CardioMEMS sensor correlated with 
Swan­Ganz catheter and echocardiographic PA pressure 
measurements. The outcomes of remote management 
of HF patients guided by wireless PA pressure moni­
toring was investigated in the landmark CHAMPION 
(CardioMEMS Heart Sensor Allows Monitoring of Pres­
sure to Improve Outcomes in NYHA Class III Heart Fai­
lure Patients) trial[16]. 
The CHAMPION trial is a randomized, controlled, 
multi­center, single­blind trial in which 550 NYHA 
class III HF patients were implanted with the wireless 
CardioMEMS HF pressure sensor system[16]. Physicians 
had access to the PA pressures of the patients in the 
treatment group only, in which medications were adjust­
ed based on the generated data. The control group 
received traditional HF management. The primary 
efficacy endpoint was the rate of HF­related hospitali­
zations at 6 mo. In comparison to the control group, 
there was a remarkable 28% reduction in HF­related 
hospitalizations at 6 mo, and 37% at 15 mo in the 
treatment group (Hazard ratio 0.63, P < 0.0001)[17]. 
There were no pressure sensor failures and 98.6% of 
the study population was free from device­related or 
system­related complications[17]. A sub­analysis of the 
original trial in HF with preserved ejection fraction (HFpEF) 
patients showed that there was a 50% reduction (P 
< 0.0001) in HF­related hospitalizations at 17 mo in 
the treatment group[18]. These landmark findings led 
to the Food and Drug Administration approval of the 
CardioMEMSTM HF system for ambulatory hemodynamic 
monitoring in NYHA class III HF with reduced ejection 
fraction (HFrEF) and HFpEF patients, who are on optimal 
medical therapy, and had a HF hospitalization in the 
previous year[19]. In the 2016 European society of 
Cardiology guidelines, CardioMEMS received a Class IIb 
recommendation for directed therapy management and 
monitoring tool in HF patients[20].
Numerous sub­analyses supported the encouraging 
results obtained from the original CHAMPION trial. The 
reduced HF­related hospitalization rate was postulated 
to be from physician controlled effective changes in 
diuretic dosing in the treatment group (P < 0.0001 for 
more frequent diuretic dose changes in treatment group 
compared to control)[21]. Wireless PA pressure­guided 
HF management was superior to clinical signs­guided 
management with a 67% relative risk reduction (P = 
0.0007) in HF hospitalizations when diuretic doses were 
adjusted based on PA pressure alone vs clinical signs 
alone[22]. At 6 mo, the target group experienced a higher 
frequency of medication adjustments with significant 
increases in the doses of diuretics, vasodilators, and 
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least 1 week before a HF hospitalization[30]. However, less 
than a half of the HF patients including those recently 
discharged after a hospitalization for HF exacerbation 
check their weight on a daily basis[31]. Daily electronic 
body weight transmission to a HF clinic in patients with 
severe HF who had a recent HF hospitalization did not 
show any benefit in reducing HF re­hospitalization or 
death[32]. 
CONCLUSION
HF continues to be a major public health problem with 
a significant financial burden. As more and more peo­
ple are living with HF, it is important have a simple, 
reliable, and valid monitoring system to aid in the early 
identification and appropriate management of worsening 
HF in the ambulatory setting. IHM is an innovative 
and exciting monitoring system for HF management. 
CardioMEMS has steered HF research into a new direction 
which will serve as the gateway to future therapies and 
innovations in the management of chronic HF patients. 
Also with increasing number of people living with LVADs 
and LVAD being used as destination therapy in a large 
percentage of the LVAD population, CardioMEMS will be 
a promising monitoring system to better manage HF 
as well as the LVAD device in this population. However, 
given the small number of participants involved in many 
of the available trials, large multicenter randomized 
clinical trials are needed to make valid recommendations 
in an effort to lower mortality and improve quality of life 
in the chronically sick HF population. Wireless left atrial 
pressure­guided and PA pressure­guided management 
of HF can have a substantial positive effect on reducing 
the financial burden of HF and improving the overall 
morbidity and mortality in this population.
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